Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for treating bladder disease in a subject, said method comprising:

administering intravesically to a subject a pharmaceutical composition comprising a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula



wherein Q is a group of the formula

$-CH_2-CH_2-$, $-CH=CH-$ or



R and R^1 are each independently C_1-C_4-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl and X^- is a physiologically acceptable anion; (2) a compound having the formula



wherein X^- is a physiologically acceptable ion; (3) a compound having the formula



wherein X^- is a physiologically acceptable ion; (4) a compound having the formula



;

wherein R_1 is 2-thienyl or cyclopentyl, and A is 3α-(6,7-dehydro)-tropanyl methobromide, 3β-tropanyl methobromide, or 3α-(N-isopropyl)-nortropanyl methobromide; (5) a compound having the formula



wherein R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} alkyl group, or R and R^1 together form a C_{4-6} alkylene group; X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_2OH, C_{1-4} alkyl or C_{1-4} alkoxy; (6) a compound having the formula



wherein R is an optionally halo- or hydroxy-substituted C_{1-4} –alkyl group, R^1 is a C_{1-4} –alkyl group, or R and R^1 together form a C_{4-6}- alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_3, CH_2OH, C_{1-4} –alkyl, or C_{1-4} –alkoxy; (7) a compound having the formula



;

(8) a compound having the formula





;

and (9) a compound having the formula





wherein X^- is a physiologically acceptable anion.

2. (Previously Presented) The method according to claim 1, wherein the compound has the formula



wherein Q is a group of the formula

$-CH_2-CH_2-$, $-CH=CH-$ or



R and R^1 are each independently C_{1-4}-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl, and X^- is a physiologically acceptable anion.

3. (Original) The method according to claim 2, wherein R is CH_3, C_2H_5, n-C_3H_7, or i-C_3H_7 and R^1 is CH_3.

4. (Original) The method according to claim 3, wherein R_1 is thienyl.

5. (Original) The method according to claim 2, wherein X^- is Br^- or CH_3SO_3.

6. (Original) The method according to claim 1, wherein the compound has the formula



wherein X^- is a physiologically acceptable ion.

7. (Withdrawn) The method according to claim 1, wherein the compound has the formula



wherein X^- is a physiologically acceptable ion.

8. (Withdrawn) The method according to claim 1, wherein the compound has the formula



R_1 is 2-thienyl or cyclopentyl, and A is 3α-(6,7-dehydro)-tropanyl methobromide, 3β-tropanyl methobromide, or 3α-(N-isopropyl)-nortropanyl methobromide.

9. (Withdrawn) The method according to claim 8, wherein R_1 is 2-thienyl and A is 3α-(6,7-dehydro)-tropanyl methobromide.

10. (Withdrawn) The method according to claim 8, wherein R_1 is 2-thienyl and A is 3β-tropanyl methobromide.

11. (Withdrawn) The method according to claim 8, wherein R_1 is cyclopentyl and A is 3α-(N-isopropyl)-nortropanyl methobromide.

12. (Withdrawn) The method according to claim 1, wherein the compound has the formula



wherein R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} alkyl group, or R and R^1 together form a C_{4-6} alkylene group; X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_3, CH_2OH, C_{1-4} alkyl or C_{1-4} alkoxy.

13. (Withdrawn) The method according to claim 12, wherein X^- is bromide.

14. (Withdrawn) The method according to claim 12, wherein R_1 is OH, CH_3, or CH_2OH.

15. (Withdrawn) The method according to claim 12, wherein R is methyl and R^1 is methyl, ethyl, n-propyl or i-propyl.

16. (Withdrawn) The method according to claim 1, wherein the compound has the formula



wherein R is an optionally halo- or hydroxy-substituted C_{1-4} –alkyl group, R^1 is a C_{1-4} –alkyl group, or R and R^1 together form a C_{4-6}- alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_2OH, C_{1-4} –alkyl, or C_{1-4} –alkoxy.

17. (Withdrawn) The method according to claim 16, wherein X^- is bromide.

18. (Withdrawn) The method according to claim 16, wherein R_1 is OH, CH_3, or CH_2OH.

19. (Withdrawn) The method according to claim 16, wherein R is methyl and R^1 is methyl, ethyl, n-propyl or i-propyl.

20. (Withdrawn-- Currently Amended) The method according to claim 1, wherein the compound has the formula





21. (Withdrawn) The method according to claim 1, wherein the compound has the formula



22. (Currently Amended) The method according to claim 1, wherein the compound has the formula



wherein X^- is a physiologically acceptable anion.

23. (Original) The method according to claim 22, wherein X^- is a bromide.

24. (Previously Presented) The method according to claim 1, wherein the pharmaceutical composition is formulated to have a prolonged duration of action.

25. (Previously Presented) The method according to claim 24, wherein the prolonged duration of action is at least about three weeks.

26. (Currently Amended) The method according to claim 1, wherein the pharmaceutical composition further comprises an additive selected from the group consisting of carboxymethyl celluloses, glycosaminoglycans, pentosan polysulfate, and heparin~~, and heparin-like compounds~~.

27. (Previously Presented) The method according to claim 1, wherein the subject has a condition selected from the group consisting of urge incontinence, cystitis, bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele, spinal cord injury, dementia where antimuscarinic medications are contraindicated, parkinsonism, and inability to tolerate systemic effects of antimuscarinic medications.